Short answer
Apogee Therapeutics, Inc. (APGE) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$86M
- −29.9% YoY · −15.8% QoQ
- EPS (diluted)
- −$1.14
- −0.9% YoY · −7.5% QoQ
Source: XBRL data from the Apogee Therapeutics, Inc. (APGE) Q2 2026 10-Q on SEC EDGAR. USD.
Apogee Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Pending AbbVie Merger remains subject to Australian ACCC review, with Phase 1 review expiring September 7, 2026
- Merger termination exposure: $381.3 million fee under specified circumstances
- New transaction risk: merger-related stockholder lawsuits following Proxy Statement demand letters disclosed August 3, 2026
- Capital risk: $160.0 million six-month net loss and $721.7 million accumulated deficit as of June 30, 2026
- Liquidity risk: additional BXLS milestone funding up to $700.0 million remains conditional
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Apogee Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.